$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Surgeons Transplant First Pig Thymokidney In EXTEND Trial

United Therapeutics said on November 20 that surgeons at NYU Langone Health performed the first transplant in its EXTEND trial of the UThymoKidney, a pig kidney with thymic tissue from an animal carrying a single gene edit, and the product remains investigational with no outcome data released.

TML Health DeskNov 20, 2:10 PM ET · 3 min read

Edited and fact-checked by Stephen Sprague

NYU Langone Health's medical center in Manhattan in an archive photo. /wikimedia
Summary

One transplant starts the trial, and the protocol's pauses will pace the evidence.

Tap a passage. React to the part that matters.

Surgeons at NYU Langone Health have transplanted a pig kidney with thymic tissue into a patient with end-stage renal disease in the EXTEND trial. United Therapeutics announced the operation on November 20, and the procedure is the first in a registered clinical trial of the UThymoKidney. The company released no information about the recipient and no outcome data, so the announcement marks a first procedure rather than a result.

Robert Montgomery led the transplant team, and he chairs the Department of Surgery at NYU Grossman School of Medicine and directs the NYU Langone Transplant Institute, and his statement framed the study as a test with a defined patient group. "The EXTEND study provides a carefully designed, scientifically rigorous way to determine whether another approach to xenotransplantation can deliver real benefit to patients who have few other options," Montgomery said. The trial enrolls patients who aren't eligible for a conventional transplant, or who sit on the Organ Procurement and Transplantation Network waitlist with odds the protocol defines as likelier to end in death or no transplant within five years than in a human kidney.

The UThymoKidney pairs a pig kidney with tissue from the same animal's thymus gland, and the thymus component is designed to help the recipient's immune system tolerate the organ, while the source pig carries a single gene edit. That figure separates this product from the company's UKidney, which carries 10 gene edits, and EXTEND is a multicenter, open-label trial registered as NCT07224763. The protocol combines phase 1, phase 2 and phase 3 stages in one design.

The trial's pacing shows how the evidence will accumulate, because the first six transplants take place at two centers with a 12-week waiting period between the first and second operations, and that pause gives investigators a window to watch the first recipient. Another patient is exposed to the same risks only after that window runs, while Jayme Locke, the company's chief medical officer for xenotransplantation, described the groundwork behind the schedule. EXTEND "reflects years of investment in the science, facilities, and regulatory groundwork needed to bring this technology from possibility to clinical reality," she said.

EXTEND is the second trial in the company's xenotransplantation program, and its sister study EXPAND began with a UKidney transplant at NYU Langone Health in November 2025, while a third product, the UHeart, sits in a study called EXPRESS. The company intends each trial to support a Biologics License Application to the Food and Drug Administration, and none of the three products holds an approval in any jurisdiction for any indication. The company states that status plainly in its announcement.

The limits of a first-procedure announcement are specific, because a single transplant can't establish safety, durability or rejection rates for a new organ source, and the announcement doesn't report kidney function, complications or the recipient's condition. It doesn't name the trial's primary endpoints or its follow-up schedule either, so readers should treat the event as the start of a measurement process. The 12-week gap before the second transplant is the first interval that can produce comparative information.

Patients with end-stage renal disease who can't receive a human kidney face dialysis as the default, and the waitlist math in the eligibility criteria describes people the current system doesn't reach in time, while EXTEND tests whether a manufactured organ supply can change that math. The trial's design answers in sequence rather than all at once, and the next verifiable milestone is the second transplant. The protocol schedules that operation only after the first recipient's 12-week window closes.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.